The United States included India, China and Pakistan in its FY2027 list of major drug transit or illicit drug-producing countries.
Inclusion in the list does not automatically mean failure to control drug trafficking, as geography, trade and economic factors are also considered.
The U.S. noted India’s efforts against illicit opium cultivation, stronger supply-chain controls and cooperation under the U.S.-India Drug Policy Framework.
China was identified as a major source of precursor chemicals used to manufacture fentanyl, methamphetamine and other synthetic drugs.
Afghanistan, Bolivia, Burma (Myanmar) and Colombia were designated as countries that had “failed demonstrably” to meet counternarcotics obligations.